U.S. markets closed

Galera Therapeutics, Inc. (GRTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.6700-0.1000 (-5.65%)
At close: 04:00PM EDT
1.8700 +0.20 (+11.98%)
After hours: 07:50PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close1.7700
Bid1.8700 x 1200
Ask1.9000 x 1000
Day's Range1.6200 - 1.7985
52 Week Range1.1500 - 10.7900
Avg. Volume220,379
Market Cap44.792M
Beta (5Y Monthly)2.41
PE Ratio (TTM)N/A
EPS (TTM)-2.9460
Earnings DateAug 08, 2022 - Aug 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for GRTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Galera Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/07/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    11 months agoArgus Research
View more
  • American City Business Journals

    Galera shares surge on news it will seek OK for lead drug candidate by year's end

    The experimental therapy is designed to treat a side effect of radiation therapy in cancer patients.

  • GlobeNewswire

    Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates

    Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022 Data from its Phase 3 ROMAN trial of avasopasem for SOM will be presented in an oral presentation at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Reported positive topline results from its Phase 2a AESOP trial of avasopasem for chemoradiotherapy-induced esophagitis MALVERN, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- G

  • GlobeNewswire

    Galera Announces Plan to Submit Avasopasem NDA by Year End

    After discussions with FDA, Company is on track to file an NDA for avasopasem for the treatment of radiotherapy-induced severe oral mucositis by end of 2022MALVERN, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced its intent to file a New Drug Application (NDA)